Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma.
Goicoechea I, Puig N, Cedena MT, Burgos L, Cordón L, Vidriales MB, Flores-Montero J, Gutierrez NC, Calasanz MJ, Ramos MM, Lara-Astiaso D, Vilas-Zornoza A, Alignani D, Rodriguez I, Sarvide S, Alameda D, Garcés JJ, Rodriguez S, Fresquet V, Celay J, Garcia-Sanz R, Martinez-Lopez J, Oriol A, Rios R, Martin-Sanchez J, Martinez-Martinez R, Sarra J, Hernandez MT, de la Rubia J, Krsnik I, Moraleda JM, Palomera L, Bargay J, Martinez-Climent JA, Orfao A, Rosiñol L, Mateos MV, Lahuerta JJ, Blade J, San Miguel J, Paiva B.
Goicoechea I, et al. Among authors: rios r.
Blood. 2021 Jan 7;137(1):49-60. doi: 10.1182/blood.2020006731.
Blood. 2021.
PMID: 32693406
Free article.
Clinical Trial.